近日， 苏州市峰郅医疗科技有限公司 宣布已成功完成 Pre-A+ 轮融资。 本轮融资由安吉两山国控集团与安吉国控建设集团联合投资，旨在为公司外周介入器械新品 的研发、产线建设、以及其主打产品 Sperstent ® 外周点状支架系统的临床注册推进提供资金支持。峰郅医疗成立仅三年，但在资本寒冬中仍连续完成多轮融资，显 示出其在技术与市场方向上的持续吸引力与执行力。 据公司表示，新一轮融资将加速其外周介入器械产品线构建和产业化进程，为填补国内外周动脉疾病介入治疗器械领域的空白提供资本与技术保障。 # 公司介绍 峰郅医疗成立于 2022 年，定位为外周血管植介入器械创新企业。公司核心团队具备医疗器械设计、材料科学、生物医学工程及产业化经验，致力于通过材料与结 构设计创新，为外周血管病变提供更安全、高效、合适国情的介入解决方案。 公司秉承"科技赋能临床、材料革新医疗"的理念，专注于解决传统外周支架治疗长期存在的"异物过量、植入硬度高、再治疗空间受限"等问题。自成立以来，峰郅 医疗已多次获得投资，其融资速度与频率在同行中较为突出，这为其产品研发、认证注册、产线建设以及市场推进奠定了坚实基础。 通过本次 Pre-A+ 融 ...

Core Viewpoint - Hainan Baimaike Medical Technology Co., Ltd. has officially received acceptance for its initial public offering (IPO) application, aiming to raise approximately 306 million RMB for its advanced medical device project, marking a significant step into the capital market for the company focused on surgical sutures and medical consumables [1][2]. Company Overview - Baimaike specializes in surgical sutures, interventional embolization materials, and hemostatic materials, with a presence in around 3,000 hospitals across China, covering all 31 provinces and regions [8]. - The company has a dual focus on consumables and medical equipment, including peptide synthesis and cleavage devices, which helps diversify its product offerings and mitigate risks associated with reliance on a single product line [14]. IPO Process - The IPO process for Baimaike has been notably swift, taking approximately six months from the completion of listing guidance in June 2025 to the acceptance announcement in December 2025 [2][6]. - The funds raised from the IPO will be allocated to expanding production, upgrading equipment automation, and establishing a materials and process research center [6][7]. Market Opportunity - The domestic surgical suture market, historically dominated by foreign brands, is experiencing a shift towards domestic alternatives due to increased demand for cost control and supply chain security in hospitals [3]. - The market for surgical sutures in China is projected to grow at a compound annual growth rate (CAGR) of nearly 9% in the coming years, driven by advancements in minimally invasive surgery and the introduction of new materials and technologies [3]. Financial Performance - Baimaike's revenue has shown significant growth, increasing from approximately 90.67 million RMB in 2022 to 185 million RMB in 2024, with net profit rising from about 29.5 million RMB to approximately 69.19 million RMB during the same period [9]. - As of mid-2025, the company reported a revenue of around 95.81 million RMB and a net profit of approximately 35 million RMB, maintaining a gross margin above 75% [9]. Product Strengths - The company's core products include absorbable surgical sutures, barbed sutures, and functional coated sutures, designed to meet the needs of various surgical departments [11]. - Baimaike's absorbable sutures are made from poly-ε-caprolactone, offering features such as knotless functionality and complete degradation within 180-220 days, which aligns with the high safety and cost-effectiveness demands of domestic hospitals [14]. Conclusion - Baimaike's journey from research to production and now to the capital market reflects the broader transition of domestic medical device companies from followers to builders in the industry [15]. - The successful fundraising and planned capacity expansion could position Baimaike as a significant player in the high-frequency surgical consumables and basic medical device sectors in China, potentially serving as a model for other domestic medical device companies [15].

Core Viewpoint - The article emphasizes the establishment of a communication platform by Suyu MedTech that connects innovators, clinicians, business managers, investors, and researchers to facilitate resource sharing and project advancement, aiming for a systematic and sustainable approach by 2026 [2]. Group 1: Conference System - The conference system will focus on "medical-engineering intersection, real-world innovation, clinical value, and industry frontiers," aiming to build a top-level communication framework within the industry [3]. - The planned conferences for 2026 include: - March 19, 2026: Third Medical Device R&D Forum in Beijing - April 24, 2026: Fourth Medical Device R&D Forum in Beijing (tentative) - May 28, 2026: Second Global Aesthetic Technology Conference in Shenzhen (tentative) - June 11, 2026: Second Global Ophthalmology Conference in Beijing - July 9, 2026: Third Global Biopharmaceutical Conference in Beijing [4][5]. Group 2: Weekly Closed-Door Activities - Starting in 2026, a weekly closed-door activity system will be established to facilitate more focused and practical exchanges [7]. - Expected themes for these activities include: 1. Global enterprise landscape and industry chain observation 2. Technological innovation in clinical scenarios 3. Market access, pricing, and insurance 4. Branding and communication strategies [8]. Group 3: Lab to Market Training Series - A systematic training course will be developed for engineers, researchers, clinicians, and entrepreneurs, focusing on the transition from lab to market [10]. - The article invites feedback from industry professionals regarding their roles, product lines of interest, industry pain points, and desired event types to tailor the activities effectively [10][12].

Core Points - The article announces the continuation of the Global MedTech Awards by Suyu MedTech to promote technological innovation and help innovative companies gain influence starting from 2023 [2] - A supplementary call for entries for innovative companies and products for the year 2025 will be open until the end of 2025 [2] Award Categories and Evaluation Criteria - **Global MedTech Industry Contribution Award**: Targeting leading medical technology companies with approved products widely used in hospitals, demonstrating significant contributions in clinical application, product innovation, economic, and social benefits [4] - **Global Medical Technology Innovation Award**: Aimed at companies with outstanding performance in medical technology innovation, focusing on products or solutions that enhance medical efficiency, improve diagnosis and treatment outcomes, and have market potential and social value [5] - **Global MedTech Rising Star Award**: For growing medical technology companies with unique technological innovation capabilities and strong market development potential [6] - **Global Innovation Medical Device Award**: For innovative medical devices approved by NMPA, FDA, or CE within 2025, recognized for their design, technology, and functionality [7] Application and Selection Process - **Application Phase**: Open from now until December 7, 2025, at 6 PM, where institutions can voluntarily submit their application materials [8] - **Selection Phase**: From now until December 15, 2025, the evaluation committee will review submissions and may contact companies for additional information [8] - **Award Notification**: Expected by December 22, 2025, with results published in an article [9] - **Award Ceremony**: Scheduled for July 2026 at the Zhongguancun Exhibition Center, with further details to be announced [9] Additional Information - Participation in the awards is free of charge, and companies that have previously submitted applications for the first batch should not resubmit [10]

Core Viewpoint - The article discusses an upcoming investment roadshow organized by the Zhongguancun Alliance for New Biomedical Industry and SiYu MedTech, aimed at connecting investors with projects in the biomedical and medical device sectors [4]. Group 1: Event Details - The roadshow will take place on December 25, 2025, at 14:00, both online via Tencent Meeting and in-person at Tsinghua Science Park [4]. - The event is free of charge and serves as a public service for alliance members, with a project vetting process in place [6]. Group 2: Participating Projects and Investors - Projects eligible for participation range from angel to Series C funding stages, covering fields such as biomedicine, medical devices, and medical aesthetics [4]. - A list of vetted investment institutions will be notified about the roadshow, including notable names like Sequoia Capital, IDG, and others [7].

Core Viewpoint - Medtronic has appointed Dr. Gerald Denny as Chief Medical Officer for its Acute Care & Monitoring (ACM) business, aiming to enhance its global medical strategy and clinical support [2]. Industry Background - The acute care and patient monitoring equipment market is crucial for ensuring patient safety and rapid medical response in hospitals, emergency rooms, and ICUs. The demand for these devices is growing due to an aging population, increasing burden of chronic and complex diseases, and hospitals' need for early warning, remote monitoring, and smart care capabilities [6]. - The development of smart monitoring and telemedicine technologies presents new opportunities for medical device manufacturers, allowing for innovation and business model upgrades [6]. - For large medical device companies, establishing robust solutions that integrate monitoring, care, emergency response, and data connectivity is essential for enhancing hospital service capabilities and addressing resource constraints [6]. Business Line Background - In October 2022, Medtronic planned to divest its patient monitoring and respiratory intervention business, valued at $9 billion, attracting interest from potential buyers like GE HealthCare and Carlyle Group. However, by February 2024, the company decided to cancel this divestiture and instead integrate the related business into a new ACM department, focusing on high-growth monitoring technologies [7][9]. - The ACM market has undergone significant changes, particularly with the decline in demand for ventilators post-COVID-19, leading to decreased profitability. Medtronic has consolidated its monitoring technologies, blood oxygen technologies, and respiratory intervention platforms into the new ACM department, which includes products like pulse oximeters and remote patient monitoring solutions [9]. - Medtronic's revenue for fiscal year 2024 was $32.4 billion, with the medical surgical product portfolio (including ACM) accounting for approximately 26%. The ACM department is seen as a growth engine within a $100 billion market potential, particularly in chronic disease management and postoperative care [9]. Appointment Significance - The appointment of Dr. Denny signifies Medtronic's commitment to enhancing clinical value and medical strategy support within its ACM business [14]. - Dr. Denny's extensive clinical and medical affairs experience is expected to improve the alignment of ACM products and technologies with clinical needs, enhancing product design and functionality [17]. - The ACM business is poised for growth due to increasing hospital demand for monitoring and emergency equipment, and Dr. Denny's leadership is anticipated to accelerate new product launches and clinical pathway integration [17]. - Having a seasoned physician and medical manager as CMO is likely to strengthen trust in Medtronic's ACM products among hospitals and clinical institutions, facilitating market expansion and academic collaboration [17]. - In the context of global healthcare resource constraints and rising demands for ICU and emergency capabilities, a focused team on acute care and monitoring is crucial for the company's future competitiveness [17].

近日，创新医疗器械公司 Xeltis 宣布完成 5500万美元融资（约合人民币3.9亿） ，用于加速其核心产品 aXess™ 可再生血管通路系统 的临床与商业化进程。 此次资金将支持Xeltis在欧洲和美国的关键注册研究、生产线扩建及早期市场推广，标志着再生型血管植入技术正式迈入规模化应用阶段。 # 血管 通路的" 再生"革 命 在慢性肾病与透析治疗领域，建立长期、稳定的血管通路始终是临床难题。 传统方法主要依赖 动静脉瘘（AVF） 或 人造血管移植（AVG） 。前者成熟慢、失功率高；后者易感染、易堵塞，且患者往往需要多次手术更换。 全球约有5000万名终末期肾病患者，每年新增透析导管手术超过300万例，医疗负担巨大。 在此背景下，兼具快速可用性与长期通畅性的"再生型血管通路"被视为下一代突破方向。 这也是Xeltis所专注的核心赛道——通过引导患者自身组织在体内"再生"出新的血管，实现从人工材料向活体组织的根本转变。 # 源自 欧洲的" 组织再生工程" 与传统人造血管（ePTFE等材料）相比，aXess™ 同时具备以下优势： Xeltis成立于2006年，总部位于瑞士苏黎世，是全球领先的 内源性组织再生（E ...

为助推技术创新，帮助创新企业和产品获得影响力，自2023年起，思宇MedTech连续评选 全球医疗科技榜单和奖项系列（Global MedTech Awards）。2023 年、2024年、2025年上半年，我们已经发布了若干奖项。现于2025年底前补录一批2025年创新企业和产品。 如果企业希望参与，请按照本通知填报，评选结果会以文章的形式发布，并在2026年7月的全球医疗科技大会上补充颁奖。 一、本次补录的奖项名称和评选规则 全球医疗科技产业贡献奖 Global MedTech Industry Contribution Award 评选对象：龙头医疗科技企业 参评标准：已有获批上市的产品，并在医院广泛应用，具有较高的行业影响力，推动了行业发展，且在临床应用、产品创新、经济效益和社会效益方面具有显 著贡献。 全球医疗技术创新奖 Global Medical Technology Innovation Award 评选对象：在医疗技术创新方面有突出表现的企业 参评标准：创新的产品或解决方案，引领细分行业科技发展趋势，能够提高医疗效率、改善诊疗效果、优化患者体验，并为医学学术做出贡献，具备市场潜力 和社会价值 ...

Core Viewpoint - Johnson & Johnson MedTech is transitioning its global business operations from a regional model to a business unit (BU) led structure starting January 1, 2026, to enhance competitiveness and value creation for customers and patients [1][4][10] Group 1: Reasons for Restructuring - The global medical device industry is undergoing significant changes, with advancements in precision medicine, minimally invasive surgery, digital health, robotics, and interventional devices, necessitating faster response times and localized compliance [3] - The traditional regional operational model of large medical device companies is seen as cumbersome and slow, hindering rapid innovation and global promotion [3] Group 2: Strategic Significance of the Restructuring - The divestiture of the orthopedic business DePuy Synthes, which previously accounted for nearly 30% of global MedTech revenue, allows the company to focus on high-growth areas such as cardiovascular, surgical, vision care, and interventional devices [4][10] - The new BU-led structure will enable faster resource allocation, enhance specialized operational capabilities, and improve product commercialization efficiency [4][9] Group 3: New Structural Arrangements - Each business unit will be responsible for its global business performance, managing everything from strategic planning to commercial execution [8] - Supply chain management will be centralized to improve global procurement and distribution efficiency [8] - Functional support departments will be restructured to align with the new BU-led operational model [8] Group 4: Expected Outcomes - The BU-led model will enhance operational efficiency and responsiveness, granting higher autonomy and decision-making flexibility to business units [9] - Resource allocation will become more concentrated and specialized, focusing on high-growth sectors [9] - Accelerated product innovation and global commercialization will be facilitated through closed-loop management from product design to global market launch [9] Group 5: Industry and Market Implications - This restructuring may serve as a trendsetter for other established medical device companies to adapt their structures in response to rapid technological and market changes [11] - The BU-led approach could shorten new product launch cycles, improving the accessibility of innovative devices and treatment solutions for hospitals and patients [11] - Increased competition dynamics may emerge in high-end interventional, digital health, and surgical device sectors, posing challenges for smaller innovative companies and new entrants [11]

Core Insights - The article emphasizes the importance of innovation in the medical technology sector, particularly in China, and aims to connect clinical practices, capital, channels, and regulations to drive high-quality development in the industry [1]. Event Overview - The event is designed for future leaders in healthcare, focusing on "thought zeroing" and "ecological linking" to foster collaboration and innovation in the medical field [3]. - The event will feature a series of workshops and discussions aimed at addressing key challenges in the medical technology industry, including the transition from laboratory to production and the identification of valuable enterprises by capital [12][13]. Workshop Highlights - Workshop 1 will focus on overcoming the "valley of death" in transitioning from laboratory innovations to production lines, featuring experts from various medical and investment backgrounds [12]. - Workshop 2 will address how innovative technologies can effectively solve clinical pain points and deliver value, with insights from medical professionals and investment experts [12]. - Workshop 3 will explore how capital can identify and support genuinely valuable companies in the new economic cycle, featuring discussions led by experienced investors and industry leaders [12]. Keynote Sessions - The keynote session will include discussions on the restructuring of medical interests and the thought processes necessary for medical enterprises to thrive in a changing landscape, led by prominent figures in the healthcare and finance sectors [13]. - Another session will provide an analysis of the macroeconomic and financial landscape in China, offering insights into how these factors impact the medical technology industry [13].